Role of Intra-Aortic Balloon Pump in Off-Pump Coronary Artery Bypass —A Vettath Modification

Objective: Hemodynamic deterioration during positioning of the heart has been the most critical complication of off-pump coronary artery bypass surgery. Pre-operative use of intra-aortic balloon pump has been shown to prevent this complication in high risk patients. The role of balloon pump in high risk patients has been questioned by our group. We modified the role of balloon pump in our patients, thus avoiding the conversion to cardiopulmonary bypass. Methods: 4063 off-pump coronary bypass surgeries were performed by a single surgeon in our center, over thirteen years. 130 intra-aortic balloons used between July 2002 and December 2015 were removed from the the-ater, once the distal anastomosis was performed. We studied this group of patients for—time and need for insertion, duration of balloon used, local insertion problems and survival. Results: Initially, we inserted intra-aortic balloons in high risk patients. We observed that, patients with low ejection fraction and patients with critical left main coronary artery disease were not the ones who actually needed balloon pump support. It was the patients who had ongoing ischemia, with preserved left ventricular function, and ST depression intra-operatively, who needed balloon pump support to perform complete anatomical revascularization. Conclusions: Intra-aortic balloon pump has helped us to position the heart without hemodynamic instability, thereby avoiding conversion to cardio-pulmonary bypass. This enabled us to perform off-pump surgery in virtually all areas of the heart, thus maintaining perfect hemodynamics.

Concurrent implantation of intra-aortic balloon pumping with extracorporeal membrane oxygenation improved survival of patients with postcardiotomy cardiogenic shock

Background Extra-corporeal membranous oxygenation (ECMO)and intra-aortic balloon pumping (IABP) are widely used in patients with severe circulatory failure. The decision to initiate ECMO and IABP on optimal occasion in postcardiotomy cardiogenic shock (PCS) remains controversial in the absence of guidelines.

Preoperative Intra-Aortic Balloon Counterpulsation in Coronary Artery Bypass Graft Patients with Severe Left Ventricular Dysfunction

Background: The intra-aortic balloon pumping (IABP) is the most used ventricular mechanical assist device. In recent years, the preoperative use in patients with severe ventricular dysfunction presents itself as a great benefic strategy to the postoperative recovery. This paper aim is to evaluate the IABP post-operative benefit in patients with severe ventricular dysfunction. Methods: From January 2011 to March 2016, 125 patients underwent a coronary artery bypass graft (CABG) with cardiopulmonary bypass and preoperative IABP in Teaching Hospital of the ABC Medical School and Hospital Estadual Mario Covas. The inclusion criteria were the presence of severe ischemic cardiomyopathy with left ventricular ejection fraction (LVEF) less than or equal to 40%, estimated by Doppler echocardiography using the Simpson method. The preoperative LVEF was 30.25% ± 8.53% and the diastolic diameter of the left ventricle (LVDD) 67.75 ± 16.37 mm. IABP was installed approximately 15 hours before the surgery. Results: The patients required the IABP for 2.4 ± 1.58 days, and vasoactive drugs, 4.8 ± 2.12 days. We performed 3.2 ± 1.9 grafts per patient and the total length of stay was 07 ± 5.52 days. Cardiopulmonary bypass time was 67 ± 10.95 minutes and anoxia time, 46.4 ± 10.06 minutes. Twelve patients (9.6%) had pneumonia and four (3.2%), atrial fibrillation. We observed a LVDD reduction to 63 ± 16.26 (p = 0.068) and LVEF enhancement to 36.50 ± 16.86 (p = 0.144). The data were analyzed statistically according to the Wilcoxon test. There were no deaths. Conclusion: The initial experience of the authors with the preoperative IABP in patients with severe left ventricular dysfunction suggests great benefit in post-operative recovery with im-provement of LVEF and reduction of LVDD.

Effects on the renal artery blood flow during the intra-aortic balloonpumping was used

The effects of intra-aortic balloon pumping(IABP) on hemodynamic parameters inthe kidney were studied. The pulse produced by pumping activated the renal nervoussystem and reduced the renal vascular resistance. Therefore, the reduction of the renalvascular resistance is an important reason for the increase the renal blood flow duringintra-aortic balloon pumping.

Anticoagulation therapy in intra-aortic balloon counterpulsation： Does IABP really need anti-coagulation ？

Objective: To investigate if intra-aortic balloon pump(IABP) is contraindicated without anticoag-ulation therapy. Methods: Some 153 IABP patients in the King Abdulaziz Cardiac Center(KSA) were random-ly assigned into two groups. Anticoagulation group( Group A) consisted of 71 patients who were given heparin intravenously with target aPTT 50 - 70 seconds. Non-anticoagulation group( Group B) consisted of 82 patients without intravenous heparin during balloon pumping. Hematological parameters including platelet count, D-dimer, Plasminogen activator inhibitor-1 (PAI-1) and fibrinogen degradation products(FDP) were checked respectively at the point of baseline, 24 hours, 48 hours and 24 hours post IABP counterpulsation. Clot deposits on balloon surface, vascular complications from IABP including bleeding and limb ischemia were recorded.Results: Platelet count and PAI-1 level decreased at 24 hours and 48 hours in both groups ( P < 0.05) . D-dimer and FDP level increased at 24 hours and 48 hours in both groups( P < 0.05), but returned to the baseline level 24 hours post IABP removal( P > 0.05) . Three patients in Group A and 2 patients in Group B developed minor limb ischemia( P > 0.05). No major limb ischemia in either group. Two patients in Group A suffered major bleeding and required blood transfusion or surgical intervention, whereas no patient had major bleeding in Group B. Eight patients had minor bleeding in Group A, but only 2 patients in Group B ( P <0.05). No clot deposit developed on IABP surface in either group. Conclusion: IABP is safe without routine anticoagulation therapy. Selecting appropriate artery approach and early detection intervention are key methods for preventing complications.

Efficacy of Intra-aortic Balloon Pump before versus after Primary Percutaneous Coronary Intervention in Patients with Cardiogenic Shock from ST-elevation Myocardial Infarction

Background： Previous studies showed that patients with cardiogenic shock （CS） from ST-elevation acute myocardial infarction （STEMI） supported by intra-aortic balloon pump （IABP） before primary percutaneous coronary intervention （PCI） decreased the risk of in-hospital mortality than patients who received IABP after PCI. However, little evidence is available on the optimal order of IABP insertion and primary PCI. The aim of this study was to investigate the impact of the sequence of IABP support and PC1 and its association with major adverse cardiac and cerebrovascular events （MACCEs）. Methods： Data were obtained from 218 consecutive patients with CS due to STEMI in Beijing Anzhen Hospital between 2008 and 2014% who were treated with 1ABP and PCI. The patients were divided into two groups： Group A in whom IABP received before PCI （n = 106） and Group B in whom IABP received after PCI （n = 112）. We evaluated the myocardial perfusion using myocardial blush grade and resolution of ST-segment elevation. The primary endpoint was 12-month risk of MACCE. Results： Most baseline characteristics were similar in patients between the two groups. However, patients received 1ABP before PCI were associated with a delay of door-to-balloon time （DBT） and higher troponin I level （P 〈 0.05）. However, myocardial perfusion was significantly improved in patients treated with IABP before PCI （P 〈 0.05）. Overall, IABP support before PCI was not associated with significantly lower risk of MACCE （P 〉 0.05）. In addition, risk of all-cause mortality, bleeding, and acute kidney injury （AKI） was similar between two groups （P 〉 0.05）. Multivariate analysis showed that DBT （odds ratio [OR] 2.5, 95% confidence interval [C/] 1.1-4.8, P=0.04）, lABP support after PCI （OR 5.7, 95% Cl 2.7-8.4, p〈0.01）, and AKI （OR 7.4, 95% CI 4.9 10.8, P- 0.01） were the independent predictors of mortality at 12-month follow-up. Conclusions： Early IABP insertion before primary PCI is associated with improved myocardial perfusion although DBT increases. IABP support before PCI does not confer a 12-month clinical benefit when used for STEMI with CS.

Peri-operative application of intra-aortic balloon pumping reduced in-hospital mortality of patients with coronary artery disease and left ventricular dysfunction

Background:There are few reports of peri-operative application of intra-aortic balloon pumping(IABP)in patients with coronary artery disease(CAD)and different grades of left ventricular dysfunction.This study aimed to analyze the early outcomes of perioperative application of IABP in coronary artery bypass grafting(CABG)among patients with CAD and left ventricular dysfunction,and to provide a clinical basis for the peri-operative use of IABP.Methods:A retrospective analysis of 612 patients who received CABG in the General Hospital of People's Liberation Army between May 1995 and June 2014.Patients were assigned to an IABP or non-IABP group according to their treatments.Logistic regression analysis was performed to investigate the influence of peri-operative IABP implantation on in-hospital mortality.Further subgroup analysis was performed on patients with severe(ejection fraction[EF]≤35%)and mild(EF=36%-50%)left ventricular dysfunction.Results:Out of 612 included subjects,78 belonged to the IABP group(12.7%)and 534 to the non-IABP group.Pre-operative left ventricular EF(LVEF)and EuroSCOREII·predicted mortality was higher in the IABP group compared with the non-IABP group(P<0.001 in both cases),yet the two did not differ significantly in terms of post-operative in-hospital mortality(P=0.833).Regression analysis showed that IABP implantation,recent myocardial infarction,critical status,non-elective operation,and postoperative ventricular fibrillation were risk factors affecting in-hospital mortality(P<0.01 in all cases).Peri-operative IABP implantation was a protective factor against in-hospital mortality(P=0.0010).In both the severe and mild left ventricular dysfunction subgroups,peri-operative IABP implantation also exerted a protective role against mortality(P=0.0303 and P=0.0101,respectively).Conclusions:Peri-operative IABP implantation could reduce the in-hospital mortality and improve the surgical outcomes of patients with CAD with both severe and mild left ventricular dysfunction.

Factors influencing outcomes of intra-aortic balloon counterpulsation in elderly patients

Background Intra-aortic balloon counterpulsation （IABP） is a mechanical cardiac-assist device that is used for cardiac support. There are no published reports about the use of IABP in elderly Chinese patients, especially for those over 80 years old. The aim of this study was to describe the clinical outcomes, influencing factors, and complications in patients 〉80 years old and requiring IABP. Methods We performed a retrospective study of 134 consecutive patients who received IABP therapy. Based on age, we defined two groups; those 〉80 years old and those 〈80 years old. Results The overall mortality was 41.8%. Patients -〉80 years old had higher mortality rates than those 〈80 years old （47.9% vs. 30.2%）. Patients 〉80 years old had fewer successful revascularizations （45.8%） and more pulmonary infections （47.9%） than patients 〈80 years old （60.3% and 30.2%, respectively）; these differences were statistically significant. The most common non-cardiac complication was pulmonary infection. Cardiogenic shock and pulmonary infection were risk factors for all-cause, in-hospital mortality, whereas revascularization success was a negative risk factor for the -〉80 years old patients. Conclusions IABP may be successfully and safely employed in patients 〉80 years old, having severe heart disease, with few complications. Patients 〉80 years old who need IABP therapy are less likely to have a successful revascularization and are more likely to develop pulmonary infections than patients 〈80 years old.

Influence of preoperative coronary collateral circulation on in-hospital mortality in patients undergoing coronary artery bypass graft surgery with intra-aortic balloon pump support

Background Outcomes in patients requiring coronary artery bypass graft （CABG） surgery have been improved with devices such as the intra-aortic balloon pump （IABP）.Good coronary collateral circulation （CCC） has been shown to reduce mortality in patients with coronary artery disease （CAD）.We aimed to investigate whether poor preoperative CCC grade is a predictor of in-hospital mortality in CABG surgery requiring IABP support.Methods Fifty-five consecutive patients who were undergoing isolated first time on-pump CABG surgery with IABP support were enrolled into this study and CCC of those patients was evaluated.Results Twenty-seven patients had poor CCC and 28 patients had good CCC.In-hospital mortality rate in poor CCC group was significantly higher than good CCC group （14 （50％） vs.4 （13％）,P=0.013）.Preoperative hemoglobin level （OR：0.752; 95％ CI,0.571-0.991,P=0.043）,chronic obstructive pulmonary disease （OR：6.731; 95％ CI,1.159-39.085,P=0.034） and poor CCC grade （OR：5.750; 95％ CI,1.575-20.986,P=0.008） were associated with post-CABG in-hospital mortality.Poor CCC grade （OR：4.853; 95％ CI,1.124-20.952,P=0.034） and preoperative hemoglobin level （OR：0.624; 95％ CI,0.476-0.954,P=0.026） were independent predictors of in-hospital mortality after CABG.Conclusion Preoperative poor CCC and hemoglobin are predictors of in-hospital mortality after CABG with IABP support.

Efficacy and safety of intra-aortic balloon pump-assisted interventional therapy in different age groups of patients with acute coronary syndrome

Background Currently intra-aortic balloon pump （IABP） has been widely used in patients with acute coronary syndrome （ACS） who undergo percutaneous coronary intervention （PCI）. However, few studies have been done with regard to the clinical outcome and safety of IABP in assisting PCI in aged patients with ACS. The purpose of the present study was to evaluate the safety of tABP in different age groups of patients with ACS.Methods Data on 292 ACS patients who received IABP-assisted PCI in Shenyang General Hospital of People＇s Liberation Army were retrospectively analyzed. More specifically, the successful rate, mortality and complications associated with the treatment were compared between the senior （〉60 years old） and the non-senior （〈60 years old） groups of patients. Results The attack rate of non-ST segment elevation ACS was significantly higher in the senior group than in the non-senior group （38.8% vs 21.1%, P 〈0.01）. The incidence of the IABP-associated complications was not significantly different between both groups （P 〉0.05）.Conclusion The clinical outcome and safety of IABP-assisted PCI in the elderly patients were comparable to that for the non-elderly patients.

Thrombocytopenia in patients of acute coronary syndrome with intra-aortic balloon pumping placement

Background Thrombocytopenia is a common complication of IABP. Until now,there is no unified conclusions about the incidence,characteristics,risk factors and the prognosis of IABP related thrombocytopenia.Methods In this study,the data of patients with ACS undergoing PCI and IABP were retrospectively analyzed.All enrolled patients were divided into thrombocytopenia group and non-thrombocytopenia group according to the occurrence of thrombocytopenia after insertion of IABP. The baseline data of the two groups were compared,and the possible risk factors of thrombocytopenia and their impact on prognosis were analyzed by chi-square test and logistic regression analysis. Results Sixty-two patients were enrolled in this study. The rate ofIABP associated thrombocytopenia was 25.8%(16/62)of all patients. Older agewas an independent risk factor of IABP associated thrombocytopenia(OR:3.625;95% confidence interval:1.016-12.935;P=0.047). The incidence of TIMI bleeding events was higher in thrombocytopenia group[75.0%(12/16)vs. 43.5%(20/46),P=0.042]. The rate of in-hospital death was similar between the two groups[18.8%(3/16)vs. 17.4%(8/46),P=1.0]. Conclusion IABP associated thrombocytopenia occurs in 25.8% of patients with ACS undergoing PCI and correlates with increased TIMI bleeding events. Older age may predict IABP associated thrombocytopenia.

Superior mesenteric artery embolism as a fatal complication of intra-aortic balloon pump: A case report and literature review

INTRODUCTION The intra-aortic balloon pump(IABP)is commonly used as a cardiac assist device in various clinical situations,including cardiogenic shock,mechanical complications of acute myocardial infarction,high risk percutaneous coronary interventions(PCI),coronary artery bypass graft surgery and refractory unstable angina,etc.However,like other invasive devices,the use of IABP has been associated with some complications.The most frequently reported complications are hemorrhage and limb ischemia.Rare complications include infection,arterial perforation,aortic dissection and thrombocytopenia and bowel infarction.Arterial embolism of internal organs is a rare but fatal complication of IABP therapy.Sirbu et al.reported that 59%of patients who developed ischemic vascular complications due to IABP died1.

Clinical significance of intra-aortic balloon pumping on no-reflow phenomenon of primary percutaneous coronary intervention for acute myocardial infarction

Background Percutaneous coronary intervention （PCI） is used as a treatment for acute myocardial infarction （AMI）, and one of its major complications is the angiographic no-reflow phenomenon （NR）. Although intra-aortic balloon pumping （IABP） is sometimes used in such patients to increase the diastolic coronary blood flow, there is little available information regarding the effects of IABP on the angiographic no-reflow phenomenon. Method Twenty-two AMI patient with NR were performed primary PCI between January 2006 and December 2009, of which 12 patients were selected for IABP therapy and the left 10 were selected as the control group by group procedure of odd and even days; We observed the vasoactive substance in both groups on the days of 1, 2, 3, 5, 7, 10 after the different interventions, which include plasma renin activity （PRA）, angiotensin Ⅱ （ANG Ⅱ）, aldosterone （ALD）, adrenaline （E）, and noradrenalin （NE）; In addition, cardiac structure and cardiac ventricle systolic function including left atrium medial diameter （LAMD）, left ventricular medial diameter （LVMD） Finally, left ventricular ejection fraction （LVEF） were evaluated after 10 days, 3 months and 6 months; statistics was taken to analysis. Results According to the time concentration curve, vasoactive substance of the IABP group decreased faster than that of the control group, and this difference had statistical significance （P 〈 0.01 ） ; In terms of LAMD, LVMD, and LVEF, echocardiography difference of the IABP and the control group in 10 days, 3 months, and 6 months also showed statistical significance （P 〈 0.05）. Conclusions IABP can significantly reduce the release of vasoactive substances of NR in patients of primary PCI for AMI; LAMD, LVMD and LVEF in 10 days, 3 months, and 6 months can be improved using this method, which is conducive to recovery of heart function.

Application of intra-aortic balloon pumping on no-reflow phenomenon in primary PCI for STEMI

Background To investigate the effect of intra-aortic balloon pumping （IABP） on no-reflow phenomenon primary percutaneous coronary intervention （PCI） for ST-Elevation Myocardial Infarction （STEMI）. Methods Clinical data of 22 acute myocardial infarction patients after PCI with angiographic no-reflow phenomenon were retrospectively analyzed between January 2006 and December 2009.12 patients underwent IABP, other 10 patients as control group. We observed difference of cardiac structure, brain natriuretic peptide （BNP） and ventricular systolic function between two group, as well as cardiac injury markers （MYO,CK-MB, cTnI） in both groups on the days of 1, 2, 3, 5, 7, 10 after the different interventions. In addition, cardiac structure and ventricular systolic function including left atrium medial diameter （LAMD）, left ventricular medial diameter （LVMD）, left ventricular ejection fraction （LVEF） was evaluated after 10 days, 3 months,6 months Finally, statistics was used to analysis the data. Results The several vasoactive substances as well as cardiac injury markers and LAMD, LVMD, LVEF of 10 days, 3 months, 6 months of IABP group were significant difference with control group significant difference （P 〉 0.0 PCI with angiographic no-reflo （P 〈 0.05）. 5）. Conclusions w phenomenon, BNP targets of IABP group compared with the control group no IABP has effects on prognosis in STEMI patients who performed which is conducive to recovery of heart function.

A comparative analysis of intra-aortic balloon pump in off-pump patients undergoing coronary artery bypass grafting at different perioperative stages

Background Intra-aortic balloon pump （IABP） has been widely used at present. We can use it at different stages of perioperative period in off-pump coronary artery bypass grafting （CABG）. However, when to used it was seldom confirmed. Methods From January 2008 to June 2012, the 89 coronary heart disease （CHD） patients accepted implantation of IABP at different stages of off-pump CABG, preoperative and postoperative ventricular systolic function, left ventricular remodeling situation and the changes of myocardial enzymes were evaluated. Results All the patients had left heart insufficiency and muhivessel disease. Their postoperative left ventricular systolic function and ventricular remodeling were significantly improved while myocardial enzymes decreased with preoperative interventional implantation of IABP. The perioperative mortality was 7.86% （7/89）. No patients had complication of IABP. Conclusion Earlier IABP implantation at preoperation is useful to improve heart function, improve the tolerability of surgery, reduce the incidence of postoperative low cardiac output syndrome （LCOS） and decrease the mortality.

急性心肌梗死合并心原性休克患者器械辅助支持下直接经皮冠状动脉介入治疗预后不良的因素分析

目的本研究旨在考察急性心肌梗死合并心原性休克患者直接经皮冠状动脉介入治疗(PPCI)术后预后不良的影响因素。方法入选2015年1月至2019年12月期间,河南中医药大学第一附属医院胸痛中心收治急性心肌梗死合并心原性休克并且行PPCI的患者,收集其临床基线特征、冠状动脉造影及PPCI相关参数、器械辅助支持信息等。根据1年内随访生存与否,分为生存组与死亡组,比较两组各项因素。结果共入选40例患者,其中生存组26例,死亡组14例。两组在基线资料、入院诊断、危险因素及合并症等方面差异均无统计学意义(均P>0.05);生存组较死亡组有入院时心率较低、血压较高的趋势;生存组心肌酶显著低于死亡组(肌酸激酶峰值:496.00(198.25,2830.00)U/L比3040.00(405.75,5626.53)U/L,P=0.003;肌酸激酶同工酶MB型峰值:52.65(31.75,219.50)U/L比306.00(27.25,489.63)U/L,P=0.006);两组间在冠状动脉造影及PPCI相关指标方面比较,生存组较对照组有更高的完全血运重建率(53.85%比21.43%,P=0.048);两组器械辅助支持方面比较,生存组较死亡组有更多的体外膜肺氧合(ECMO)联合主动脉内球囊反搏(IABP)支持的比例(38.46%比7.14%,P=0.034)。结论急性心肌梗死合并心原性休克行PPCI的患者的预后与心肌酶水平、ECMO联合IABP支持以及完全血运重建有关。

早期与晚期支架内血栓致4b型急性心肌梗死患者临床结局比较

目的比较早期与晚期支架内血栓(ST)致4b型急性心肌梗死(AMI)患者院内及出院1年生存及预后情况。方法入选2015年1月—2018年2月冠状动脉造影确定ST致4b型AMI患者共302例。根据ST发生时间分为早期ST组(≤30 d)26例和晚期ST组(>30 d)276例,对比2组患者住院期间及出院1年内的终点事件。主要研究终点包括心源性死亡和再发AMI;次要研究终点包括靶病变血运重建(TLR)、再次ST、心力衰竭及卒中。采用Kaplan-Meier法绘制生存曲线并比较2组患者无终点事件发生率;采用Cox回归分析4b型AMI患者发生终点事件的危险因素。结果住院期间2组主要研究终点事件发生率差异无统计学意义(7.7%vs.3.3%,P=0.243);早期ST组院内心力衰竭发生率高于晚期ST组(11.5%vs.1.4%,P=0.016),其他次要终点事件发生率差异无统计学意义(P>0.05)。平均随访1年,早期ST组主要(20.0%vs.5.9%,P<0.05)及次要(36.0%vs.11.5%,P<0.05)研究终点事件发生率均高于晚期ST组。Kaplan-Meier生存分析表明,早期ST组1年累积无主要(P=0.022)及次要(P<0.001)终点事件发生率均低于晚期ST组。Cox回归分析表明高血压、冠状动脉旁路移植术史是4b型AMI患者发生主要终点事件的独立危险因素,术中植入主动脉内气囊泵(IABP)、缩短支架内血栓至球囊扩张(ST to B)时间是其发生次要终点事件的独立保护因素。结论与晚期ST致4b型AMI患者相比,早期ST患者院内结局相似,长期预后差。术中植入IABP、缩短ST to B时间可能改善4b型AMI患者预后。

急性心肌梗死主动脉内球囊反搏术后发生缺血性肠病一例

1病例资料患者男性,67岁,因“胸闷7 d,再发加重10 h”于2023年2月9日入院。患者于7 d前无明显诱因出现胸闷不适,主要位于胸骨左缘,持续约10 min,伴气短,休息后症状稍缓解,期间发作数次。于10 h前上述症状再发加重,持续无缓解,遂来院就诊。既往史:高血压病史10年,最高血压170/90 mmHg,口服培哚普利治疗,血压控制尚可.

左西孟旦联合主动脉球囊反搏可有效改善急性心肌梗死合并心源性休克患者的预后

目的:本研究评估左西孟旦联合主动脉球囊反搏(IABP)对急性心肌梗死(AMI)合并心源性休克(CS)患者的疗效及安全性。方法:连续收集AMI合并CS植入IABP行急性经皮冠状动脉介入治疗(PCI)患者82例,随机分为观察组(左西孟旦+IABP)和对照组(单纯IABP),使用化学发光法检测2组血清N末端-脑钠肽前体(NT-proBNP)、肌钙蛋白I(cTnI)水平,使用酶联免疫吸附检测超敏C反应蛋白(HsCRP)的水平。统计患者IABP辅助时间、CCU入住天数及总住院天数;心肌梗死后30 d心脏主要不良事件发生情况:再发心肌梗死、脑卒中、再次血运重建、死亡及再次住院率。结果:治疗5 d后,与对照组比较,观察组患者NT-proBNP下降更加明显[(-3895.37±1589.59) pg/mL vs(-2568.53±1864.23)pg/mL,P=0.0026],hsCRP降低更加显著[(-42.56±20.35)mg/L vs(-25.63±12.69)mg/L,P=0.0032],肌钙蛋白峰值更低[(89.65±36.58)ng/mL vs(98.56±32.69)mg/L,P=0.042];观察组IABP持续时间更短[(4.5±2.5)d vs(6.5±3.5)d,P=0.032],CCU入住时间更短[(7.5±3.5)d vs(9.5±4.5)d,P=0.039],总住院时间明显降低[(10.5±5.5)d vs(13.5±6.5)d,P=0.025]。2组患者住院期间死亡率比较,差异无统计学意义(P=0.696)。观察组30 d内心血管主要不良事件发生率低于对照组(19.05%vs 25.00%,P=0.515),急诊就医次数更少[(1.2±0.8)vs(2.2±1.8),P=0.042],再次住院次数更少[(0.8±1.2)vs(1.5±1.6),P=0.049]。出院时,观察组标准EQ-5D-3L健康调查问卷评分低于对照组(P=0.038),随访30 d时继续保持降低(P=0.029)。结论:左西孟旦联合IABP对AMI合并CS患者疗效肯定且安全可靠。

PCI联合主动脉内球囊反搏治疗老年急性心肌梗死合并心力衰竭的临床研究

目的:探讨老年急性心肌梗死(AMI)合并心力衰竭病人采用经皮冠状动脉介入术(PCI)联合主动脉内球囊反搏(IABP)治疗的临床效果。方法:回顾性选取2018年9月—2020年9月四川大学华西医院收治的老年AMI合并心力衰竭病人103例,其中采用IABP联合PCI治疗的52例病人作为联合组,另选取同期收治的仅采用PCI治疗的51例病人作为对照组。比较两组治疗后心肌梗死溶栓试验(TIMI)血流分级、心肌酶学指标、心功能指标、不良心血管事件(MACE)发生率。结果:治疗后,联合组靶血管TIMI血流分级优于对照组(P<0.05)。治疗后,两组血清肌酸激酶同工酶(CK-MB)、肌钙蛋白I(cTnI)、乳酸脱氢酶(LDH)、肌钙蛋白T(cTnT)水平均较治疗前明显降低(P<0.05),但两组治疗后各指标比较差异无统计学意义(P>0.05)。治疗后,联合组左室射血分数(LVEF)高于对照组,左室收缩末期内径(LVESD)、氨基末端脑钠肽前体(NT-proBNP)低于对照组,差异均有统计学意义(P<0.05)。随访24个月,联合组MACE发生率为5.77%,低于对照组的21.57%,差异有统计学意义(P<0.05)。结论:采用IABP联合PCI治疗AMI合并心力衰竭的老年病人,可促进心功能恢复、靶血管血流恢复,降低MACE发生率。